TARS

Tarsus Pharmaceuticals (TARS) has gained 2.5% over the past four weeks and closed at $74.85. Wall Street analysts project a mean price target of $97.89, indicating potential upside of 30.8%.

The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions with the consensus estimate increasing 3.1% over the past month. However, the article cautions that price targets alone should not be the sole basis for investment decisions.

Tarsus Pharmaceuticals is expected to report a quarterly loss of $1.43 per share (down 376.7% YoY) with revenues of $188.8 million (up 59.1% YoY) for Q3 2026. The company has a negative Earnings ESP of -40.31% combined with a Zacks Rank #2, making it unlikely to beat consensus estimates. The company has a mixed earnings surprise history, beating estimates in 2 of the last 4 quarters.

Harmony Biosciences is expected to report Q3 2026 earnings on November 4, with Wall Street anticipating 14.9% YoY EPS growth to $1.00 per share and 13.1% revenue growth to $270.87 million. However, a negative Earnings ESP of -12.00% combined with recent downward estimate revisions suggests the stock may not beat consensus expectations, despite carrying a Zacks Rank #1 rating.